# An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

> **NCT07101705** · EARLY_PHASE1 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma (MM)
- Non-Hodgkin Lymphoma (NHL)

## Interventions

- **DRUG:** OriV508 Injection

## Key facts

- **NCT ID:** NCT07101705
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101705, "An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07101705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*